Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Extrawell Pharmaceutical Holdings Limited ( (HK:0858) ) has provided an announcement.
Extrawell Pharmaceutical has agreed with bondholder Starcoin to extend the long stop date for completing the fourth set of amendments to its bond terms from 31 March 2026 to 30 June 2026. The change allows more time to satisfy precedent conditions and preserves the effectiveness of the amendment deed, reducing the risk that the revised bond arrangements lapse and potentially easing near-term financing uncertainty.
The company also announced a delay in sending a shareholder circular on the major transaction related to the bond amendments, pushing the expected despatch date from on or before 6 March 2026 to on or before 30 May 2026. This postponement, driven by the need to finalise information, slows the timetable for shareholder approval via a special general meeting and may briefly extend uncertainty for investors assessing the impact of the revised bond terms.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.08 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
More about Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited is a Hong Kong-listed pharmaceutical company incorporated in Bermuda and traded under stock code 00858. The group operates in the healthcare sector, focusing on the development and commercialisation of pharmaceutical products for the Chinese and broader Asian markets, serving shareholders through capital markets in Hong Kong.
Average Trading Volume: 2,172,033
Technical Sentiment Signal: Sell
Current Market Cap: HK$209.1M
For an in-depth examination of 0858 stock, go to TipRanks’ Overview page.